# Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis

> **NCT01894373** · PHASE1,PHASE2 · COMPLETED · sponsor: **Chinese PLA General Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Psoriasis
- Adoptive Immunotherapy

## Interventions

- **DRUG:** Adoptive Immunotherapy
- **BIOLOGICAL:** CIK

## Key facts

- **NCT ID:** NCT01894373
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2018-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01894373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01894373, "Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01894373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*